The A-BRAVE trial showed that adjuvant avelumab improved 3-year overall survival in patients with early triple-negative breast cancer and high risk of recurrence. The treatment reduced the risk of distant metastasis and death by 30% and 34%, respectively. While the study did not meet its primary endpoint of disease-free survival, secondary and exploratory endpoints showed significant benefits. Avelumab, a weak PD-L2 inhibitor, may have a role in this patient population. Further research, such as SWOG1814, will provide more information on adjuvant checkpoint blockade therapy. The study was funded by Merck KGaA, and the researchers disclosed various financial relationships.
Source link
Adjuvant Avelumab Benefits Seen in High-Risk TNBC
